Dr. P. Vijaya, Dr. Sowmya Patnala


Objective: It is a prospective randomized study to see the efficacy of PGE1 in cases of PROM from 28wks to term gestational age evaluating the mode of delivery with perinatal and maternal outcome. This study was conducted at Mahavir Institute of Medical Sciences, Vikarabad during 1/1/2018 to 30/12/2018.

Methodology: Women with PROM history with unfavourable cervix misoprostol 25micrograms orally 4th hrly up to a maximum of 6 doses given. Bishops score was assessed and labour augmented using oxytocin as and when required. Contractions monitored with CTG. Vaginal examination done 4-6hrly to assess the progress of labour.

All the women were monitored with continuous CTG. Primary (time interval from induction to delivery, percentage of women delivered within 24 hrs. vaginally, rate of LSCS) and Secondary (need of oxytocin acceleration, neonatal morbidity and mortality, maternal morbidity and mortality) outcomes noted.

Results: Out of 100 cases 81 delivered vaginally, 19 cases LSCS done. In term PROM cases -100% survival. Among preterm PROM 21/100, 2 were IUD on admission, 3 neonatal deaths. Total perinatal mortality 3% in 100 cases of PROM No. of NICU admissions 10/100-10%. According to birth weights IUD babies were 750, 800gms. NND two were<1.2kg. NND 1baby was 1.8kg. Mean birth weight of NND –1.2kg. Birth weight of >1.8kgs all the babies survived.                

Conclusion: PGE1 Misoprostol is effective for cervical ripening and inducing labour in PROM cases as seen in our study with 100% perinatal survival in term PROM and LSCS rate of 19%. In our study we did not have PPH or hyper stimulation.

Hence low dose PGE1 25 micrograms is efficient and cost effective as an inducing agent orally also.



PROM-preterm rupture of membranes, PG Prostaglandin, PGE1-prostaglandin E1, NICU-neonatal intensive care unit, NND-neonatal death, IUD-intrauterine death, CTG-cardiotocography, LSCS-lower segment caesarean section, FHR-fetal heart Rate, PPH-Post-partum ha

Full Text:



American College of Obstetricians and Gynaecologists: ACOG Practice Bulletin No.107: Induction of labor. Obstet Gynecol 2009 ; 114:386.Reaffirme d2019

AlfirevicZ; Aflaifel N, WeeksA. Oral misoprostol for induction of labour. Cochrane Database Syst Rev.2014;(6):Art.No:CD 001338

NgaiSW, To WK, Lao T, HoPC. Cervical priming with oral misoprostol in prelabour rupture of membranes at term. Obstet Gynecol 1996;87:923-6

Dyar TR, Greig P, Cummings R, Nichols K. The efficacy and safety of oral versus vaginal misoprostol for the induction of term labor. Am J Obstet Gynecol 2000;182:S135

AriasF. Pharmacology of oxytocin and prostaglandins. Clin Obstet Gynecol 2000;43:455-468

AlfirevicZ, Keeney E, Dowswell T et al. Labour induction with prostaglandins: a systematic review and network meta-analysis.BMJ 2015;350:217

World Health Organization (WHO), Dept of Reproductive Health and Research. WHO recommendations for induction of labour.Geneva;WHO,2011

KhanRV, EL-Refaey H, Sharma S. Oral, rectal and vaginal pharmokinetics of misoprostol. Obstet Gynecol 2004;1o3:866

Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior caesarean delivery. N.Engl J Med 2001; 345:3

Weeks AD, Navaratnam K, Alfirevic Z. Simplifying oral misoprostol protocols for the induction of labour. BJOG 2017;124:1642

Kundodyiwa TW, Alfirevic Z. Weeks AD. Low dose oral misoprostol for induction of labour: a systematic review. Obstet Gynecol 2009;113:374


  • There are currently no refbacks.